Alexandra Lansky, MD, discusses a propensity-adjusted population-based analysis of Impella in patients undergoing high-risk PCI from a large-scale claims dataset.
A study of 21,848 non-emergent, high-risk patients who underwent PCI with PVADs, including Impella® heart pumps, demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with IABPs.
Gregg Stone, MD, and Duane Pinto, MD, host this panel discussion from SCAI 2021 of Protected PCI and diagnosis and treatment of high-risk and complex coronary disease.
Ziad Ali, MD, presents a case study illustrating imaging-guided PCI in the context of high-risk Protected PCI at the CRT 2021 virtual annual symposium.
The PROTECT IV RCT will leverage advancements in technology and best practices learned since the completion of the PROTECT II RCT and the FDA pre-market approval for Impella 2.5® for high-risk PCI.
This live case highlights high-risk PCI involving a calcified graft lesion treated with orbital atherectomy and stenting with Impella heart pump hemodynamic support.
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.